High expression of neutrophil and monocyte CD64 with simultaneous lack of upregulation of adhesion receptors CD11b, CD162, CD15, CD65 on neutrophils in severe COVID-19.
CD 162
CD11b
CD15
CD64
CD65
COVID-19
monocyte
neutrophil
Journal
Therapeutic advances in infectious disease
ISSN: 2049-9361
Titre abrégé: Ther Adv Infect Dis
Pays: England
ID NLM: 101606715
Informations de publication
Date de publication:
Historique:
received:
25
05
2021
accepted:
02
07
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
The pronounced neutrophilia observed in patients with coronavirus disease 2019 (COVID-19) infections suggests a role for these leukocytes in the pathology of the disease. Monocyte and neutrophil expression of CD64 and CD11b have been reported as early biomarkers to detect infections. The aim of this study was to study the expression of receptors for IgG (CD64) and adhesion molecules (CD11b, CD15s, CD65, CD162, CD66b) on neutrophils and monocytes in patients with severe COVID-19 after admission to an intensive care unit (ICU). The expression of receptors was analyzed using flow cytometry. EDTA blood from 23 patients with confirmed COVID-19 infection was sampled within 48 h of admission to the ICU. Leukocytes were labeled with antibodies to CD11b, CD15s, CD65s, CD162, CD64, and CD66b. Expression of receptors was reported as mean fluorescence intensity (MFI) or the percentage of cells expressing receptors. Results are presented as comparison of COVID-19 patients with the healthy group and the receptor expression as MFI. Neutrophil receptors CD64 (2.5 Monocytes and neutrophils are activated during severe COVID-19 infection as shown by strong upregulation of CD64. High monocyte and neutrophil CD64 can be an indicator of a severe form of COVID19. The adhesion molecules (CD11b, CD162, CD65, and CD15) are not upregulated on otherwise activated neutrophils, which might lead to relative impairment of tissue migration. Low adhesion profile of neutrophils suggests immune dysfunction of neutrophils. Monocytes maintain upregulation of some adhesion molecules (CD11b, CD162) suggesting the persistence of an increased ability to migrate into tissues, even during a severe stage of COVID-19. Future research should focus on CD64 and CD11b kinetics in the context of prognosis.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The pronounced neutrophilia observed in patients with coronavirus disease 2019 (COVID-19) infections suggests a role for these leukocytes in the pathology of the disease. Monocyte and neutrophil expression of CD64 and CD11b have been reported as early biomarkers to detect infections. The aim of this study was to study the expression of receptors for IgG (CD64) and adhesion molecules (CD11b, CD15s, CD65, CD162, CD66b) on neutrophils and monocytes in patients with severe COVID-19 after admission to an intensive care unit (ICU).
METHODS
METHODS
The expression of receptors was analyzed using flow cytometry. EDTA blood from 23 patients with confirmed COVID-19 infection was sampled within 48 h of admission to the ICU. Leukocytes were labeled with antibodies to CD11b, CD15s, CD65s, CD162, CD64, and CD66b. Expression of receptors was reported as mean fluorescence intensity (MFI) or the percentage of cells expressing receptors.
RESULTS
RESULTS
Results are presented as comparison of COVID-19 patients with the healthy group and the receptor expression as MFI. Neutrophil receptors CD64 (2.5
CONCLUSION
CONCLUSIONS
Monocytes and neutrophils are activated during severe COVID-19 infection as shown by strong upregulation of CD64. High monocyte and neutrophil CD64 can be an indicator of a severe form of COVID19. The adhesion molecules (CD11b, CD162, CD65, and CD15) are not upregulated on otherwise activated neutrophils, which might lead to relative impairment of tissue migration. Low adhesion profile of neutrophils suggests immune dysfunction of neutrophils. Monocytes maintain upregulation of some adhesion molecules (CD11b, CD162) suggesting the persistence of an increased ability to migrate into tissues, even during a severe stage of COVID-19. Future research should focus on CD64 and CD11b kinetics in the context of prognosis.
Identifiants
pubmed: 34377464
doi: 10.1177/20499361211034065
pii: 10.1177_20499361211034065
pmc: PMC8326822
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20499361211034065Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare that there is no conflict of interest.
Références
Clin Rheumatol. 2019 May;38(5):1319-1328
pubmed: 30915651
J Thromb Haemost. 2021 Feb;19(2):574-581
pubmed: 33217134
J Infect. 2010 May;60(5):313-9
pubmed: 20206205
J Immunol. 2018 Mar 1;200(5):1771-1780
pubmed: 29343555
Hypertension. 2020 Oct;76(4):1104-1112
pubmed: 32673499
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
J Leukoc Biol. 1992 Feb;51(2):157-63
pubmed: 1431552
J Crit Care. 2018 Feb;43:139-142
pubmed: 28898742
Leuk Res. 2001 Oct;25(10):847-53
pubmed: 11532516
Crit Care Clin. 2017 Apr;33(2):277-292
pubmed: 28284295
Acta Anaesthesiol Scand. 2015 Aug;59(7):881-91
pubmed: 25866876
Scand J Immunol. 1999 Oct;50(4):433-9
pubmed: 10520185
Cardiovasc Res. 2015 Aug 1;107(3):331-9
pubmed: 25994174
Front Immunol. 2018 Oct 02;9:2171
pubmed: 30356867
J Infect Dis. 2020 Nov 13;222(12):1985-1996
pubmed: 32941618
J Immunol. 1995 Nov 15;155(10):4979-90
pubmed: 7594504
Biomed Res Int. 2020 Aug 7;2020:6214363
pubmed: 32832553
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
Am J Physiol Lung Cell Mol Physiol. 2013 Nov 15;305(10):L756-63
pubmed: 24039252
Respir Res. 2013 Jul 08;14:72
pubmed: 23834268
Blood Adv. 2021 Mar 9;5(5):1164-1177
pubmed: 33635335
J Immunol Methods. 2004 Oct;293(1-2):207-14
pubmed: 15541289
Scand J Infect Dis. 2005;37(11-12):882-9
pubmed: 16308225
Intensive Care Med. 2005 Oct;31(10):1345-55
pubmed: 16132892
J Infect Dev Ctries. 2016 Mar 31;10(3):260-8
pubmed: 27031458
PLoS One. 2020 Nov 18;15(11):e0241659
pubmed: 33206680
J Immunol. 2009 Aug 15;183(4):2349-55
pubmed: 19635920
Int J Microbiol. 2020 Nov 1;2020:8814892
pubmed: 33204274
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
Eur J Haematol. 1993 Oct;51(4):187-98
pubmed: 8243606
Scand J Immunol. 2016 Dec;84(6):332-337
pubmed: 27606963
Nat Med. 2020 Nov;26(11):1701-1707
pubmed: 32812012
Immunity. 2002 Mar;16(3):391-402
pubmed: 11911824
Semin Cancer Biol. 1999 Apr;9(2):67-81
pubmed: 10202129
J Immunol Methods. 1992 Feb 5;146(2):219-28
pubmed: 1347052
J Immunol. 1990 Sep 1;145(5):1337-42
pubmed: 2143517
Scand J Infect Dis. 2008;40(4):326-37
pubmed: 17918019
Cytokine. 2021 Feb;138:155389
pubmed: 33348065
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
Med Sci Monit. 2019 Oct 15;25:7728-7734
pubmed: 31612870
Br J Gen Pract. 2014 Dec;64(629):604-5
pubmed: 25452508
BMJ Open. 2019 May 1;9(4):e025222
pubmed: 31048432